United Capital Financial Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

United Capital Financial Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-11,262	Closed	-$275K	–	1197
2021 Q2	$275K	Sell	11,262 -4,350	-28%	-$98.2K	﹤0.01%	1049
2021 Q1	$403K	Sell	15,612 -626	-4%	-$27.6K	﹤0.01%	911
2020 Q4	$868K	Sell	16,238 -3,661	-18%	-$182K	0.01%	712
2020 Q3	$821K	Buy	19,899 +1,051	+6%	+$45.4K	0.01%	708
2020 Q2	$914K	Buy	18,848 +403	+2%	+$19.3K	0.01%	688
2020 Q1	$779K	Sell	18,445 -317	-2%	-$13.1K	0.01%	692
2019 Q4	$803K	Hold	18,762	–	–	0.01%	849
2019 Q3	$675K	Buy	+18,762	New	+$569K	﹤0.01%	859
2017 Q1	–	Sell	-6,989	Closed	-$202K	–	1238
2016 Q4	$202K	Sell	6,989 -5,158	-42%	-$136K	﹤0.01%	1184
2016 Q3	$386K	Sell	12,147 -620	-5%	-$21K	﹤0.01%	1018
2016 Q2	$409K	Buy	+12,767	New	+$427K	﹤0.01%	963

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

United Capital Financial Advisors's ACAD Position: Q3 2021 in Review

United Capital Financial Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q3 2021, closing a stake of 11,262 shares — an estimated $275K sold.

United Capital Financial Advisors first reported a position in ACAD in Q2 2016 and held it in 11 quarters. The position peaked at $914K in Q2 2020. 237 funds tracked by Wall St. Rank hold ACAD as of Q3 2021.

United Capital Financial Advisors reported no remaining Acadia Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
United Capital Financial Advisors sold 11,262 Acadia Pharmaceuticals shares in Q3 2021, an estimated $275K.
United Capital Financial Advisors first reported a position in Acadia Pharmaceuticals in Q2 2016 and held it in 11 quarters.
United Capital Financial Advisors's Acadia Pharmaceuticals position peaked at $914K in Q2 2020.
237 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2021.

Based on United Capital Financial Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.